Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87861
Title:
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Authors:
Woll, Penella J; Judson, I; Lee, Siow Ming; Rodenhuis, Sjoerd; Nielsen, O S; Buesa, J M; Lorigan, Paul C ( 0000-0002-8875-2164 ) ; Leyvraz, Serge; Hermans, C; Van Glabbeke, Martine M; Verweij, Jaap
Abstract:
Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.
Affiliation:
City Hospital, Nottingham, U.K. penella.woll@nott.ac.uk
Citation:
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. 1999, 35 (3):410-2 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Mar-1999
URI:
http://hdl.handle.net/10541/87861
DOI:
10.1016/S0959-8049(98)00403-1
PubMed ID:
10448291
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorJudson, Ien
dc.contributor.authorLee, Siow Mingen
dc.contributor.authorRodenhuis, Sjoerden
dc.contributor.authorNielsen, O Sen
dc.contributor.authorBuesa, J Men
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorLeyvraz, Sergeen
dc.contributor.authorHermans, Cen
dc.contributor.authorVan Glabbeke, Martine Men
dc.contributor.authorVerweij, Jaapen
dc.date.accessioned2009-12-14T14:39:36Z-
dc.date.available2009-12-14T14:39:36Z-
dc.date.issued1999-03-
dc.identifier.citationTemozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. 1999, 35 (3):410-2 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid10448291-
dc.identifier.doi10.1016/S0959-8049(98)00403-1-
dc.identifier.urihttp://hdl.handle.net/10541/87861-
dc.description.abstractTemozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshDacarbazine-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshSarcoma-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleTemozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.en
dc.typeArticleen
dc.contributor.departmentCity Hospital, Nottingham, U.K. penella.woll@nott.ac.uken
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.